These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19553795)

  • 21. Genetics of age-related macular degeneration.
    Ting AY; Lee TK; MacDonald IM
    Curr Opin Ophthalmol; 2009 Sep; 20(5):369-76. PubMed ID: 19587596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Angiogenic inhibitors and radiotherapy: from the concept to the clinical trial].
    Cohen-Jonathan Moyal E
    Cancer Radiother; 2009 Oct; 13(6-7):562-7. PubMed ID: 19695923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy using the small interfering RNA bevasiranib.
    Singerman L
    Retina; 2009 Jun; 29(6 Suppl):S49-50. PubMed ID: 19553802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
    Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
    Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities and challenges in the development of combination therapy for the treatment of retinal diseases.
    Hohman TC
    Retina; 2009 Jun; 29(6 Suppl):S51-3. PubMed ID: 19553804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Modern radiation therapy].
    Kouri M; Kangasmäki A
    Duodecim; 2009; 125(9):947-58. PubMed ID: 19517863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration.
    Tsuchihashi T; Mori K; Peyman G; Shimada Y; Yoneya S
    Retina; 2009; 29(10):1450-6. PubMed ID: 19816240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation therapy for age-related 'wet-type' macular degeneration.
    Brady LW; Lahaniatis JE; Freire JE; Miyamoto CT; Micaily B; Yaeger TE
    Front Radiat Ther Oncol; 2001; 35():79-85. PubMed ID: 11351956
    [No Abstract]   [Full Text] [Related]  

  • 32. Advancement of antiangiogenic and vascular disrupting agents combined with radiation.
    Citrin D; Camphausen K
    Cancer Treat Res; 2008; 139():153-71. PubMed ID: 18236716
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment planning with heavy ions.
    Chauvel P
    Radiat Environ Biophys; 1995 Mar; 34(1):49-53. PubMed ID: 7604161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population.
    Janik-Papis K; Zaras M; Krzyzanowska A; Wozniak K; Blasiak J; Szaflik J; Szaflik JP
    Exp Mol Pathol; 2009 Dec; 87(3):234-8. PubMed ID: 19761764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rationale for drug combinations in age-related macular degeneration.
    Adamis AP
    Retina; 2009 Jun; 29(6 Suppl):S42-4. PubMed ID: 19553800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA damage and repair in age-related macular degeneration.
    Szaflik JP; Janik-Papis K; Synowiec E; Ksiazek D; Zaras M; Wozniak K; Szaflik J; Blasiak J
    Mutat Res; 2009 Oct; 669(1-2):169-76. PubMed ID: 19559717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron and age-related macular degeneration.
    Błasiak J; Skłodowska A; Ulińska M; Szaflik JP
    Klin Oczna; 2009; 111(4-6):174-7. PubMed ID: 19673453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
    Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
    Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group.
    ; Solomon SD; Jefferys JL; Hawkins BS; Bressler NM; Bressler SB
    Retina; 2009 Sep; 29(8):1080-90. PubMed ID: 19734762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
    Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
    Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.